← Back to Search

Checkpoint Inhibitor

Stereotactic Body Radiation Therapy for Cancer (C4-MOSART Trial)

Phase 1

Waitlist Available

Led By Jason Luke, MD

Research Sponsored by University of Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 - 24 months

Awards & highlights

C4-MOSART Trial Summary

This trial is studying how well different doses of SBRT work when given with immunotherapy drugs to treat patients with cancer that has spread to other parts of the body.

C4-MOSART Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 - 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 - 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 - 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Recommended dose of SBRT given in combination with immunotherapy

Secondary outcome measures

Local disease control of SBRT treated lesions

Overall survival rate

Progression free survival rate

+3 more

Side effects data

From 2022 Phase 2 trial • 29 Patients • NCT02045446

79%

Cough

64%

Dyspnea

64%

Nausea

57%

Fatigue

43%

Constipation

36%

Pain

36%

Dizziness

29%

Anemia

29%

Back pain

29%

Vomiting

21%

Chest pain

21%

Lymphocyte count decreased

21%

Death NOS

21%

Anorexia

21%

Anxiety

21%

Fall

14%

Wheezing

14%

Hypotension

14%

Depression

14%

Diarrhea

14%

Dysphagia

14%

Platelet count decreased

14%

Abdominal Pain

14%

Edema

14%

Fever

14%

Headache

14%

Insomnia

14%

Palpitations

Dysuria

Hemorrhoids

Dehydration

Dysgeusia

Amnesia

Hypertension

Confusion

Hypernatremia

Creatinine increased

Dementia

Productive cough

Pneumonitis

White blood cell count decreased

Throat pain

Bone marrow biopsy

Blurred vision

Hearing impaired

Rash

Eye pain

Tachycardia

Lung infection

Neuropathy

Pleuritic pain

Neutropenia

Hypoxia

Aspiration pneumonia

Blood bilirubin increased

Muscle weakness

Tremor

Weight loss

Thrombocytopenia

Floaters

Toothache

Sinusitis

Alopecia

Esophagitis

Otitis externa

Leukocytosis

Edema limbs

Gait disturbance

Parathesia (tingling)

Edema face

COPD

100%

80%

60%

40%

20%

Study treatment Arm

Stereotactic Body Radiation Therapy

Maintenance Chemotherapy

C4-MOSART Trial Design

2Treatment groups

Experimental Treatment

Group I: SBRT with Nivolumab and UrelumabExperimental Treatment3 Interventions

Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.

Group II: SBRT with Nivolumab and CabiralizumabExperimental Treatment3 Interventions

Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cabiralizumab

2018

Completed Phase 2

~620

Urelumab

2013

Completed Phase 1

~240

Stereotactic Body Radiation Therapy

2012

Completed Phase 2

~780

Nivolumab

2014

Completed Phase 3

~4750

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor

1,000 Previous Clinical Trials

817,570 Total Patients Enrolled

Bristol-Myers SquibbIndustry Sponsor

2,634 Previous Clinical Trials

4,126,795 Total Patients Enrolled

Jason Luke, MDPrincipal InvestigatorUniversity of Chicago

3 Previous Clinical Trials

711 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Recent research and studies

clinicaltrials.govStudy

Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

2018. "Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03431948.

~8 spots leftby Apr 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.